Volume 12, Number 1—January 2006
Research
Economics of Neuraminidase Inhibitor Stockpiling for Pandemic Influenza, Singapore
Table 3
Cost-benefit and cost-effectiveness with changes in prophylaxis stockpile for the Singapore population*†
Strategy option | Stockpile cost (1 cycle, million $) | Lives saved compared with no action | Cost per life saved compared with no action ($100,000) | Benefit compared with no action (million $) |
---|---|---|---|---|
No action | Not applicable | Deaths: 1,105 (525, 1,775) | Not applicable | Cost: 1,430 (730, 2,193) |
Only Rx‡ | 79 | 423 (183, 756) | 38 (dominates§, 395) | 379 (89, 734) |
6 wk¶ | 631 | 492 (216, 870) | 2,246 (811, 4,676) | –487 (–925, 48) |
12 wk¶ | 1183 | 684 (286, 1,264) | 3,193 (1,008, 6,788) | –1,188 (–1,934, –265) |
18 wk¶ | 1735 | 850 (377, 1,442) | 3,668 (1,358, 7,363) | –1,920 (–2,941, –783) |
24 wk¶ | 2,287 | 903 (425, 1,509) | 4,516 (1,828, 9,022) | –2,811 (–4,070, –1,384) |
*Mean values are shown with 5th and 95th percentiles in parentheses.
†All healthcare costs are in 2004 Singapore dollars.
‡Only Rx refers to treatment only, without prophylaxis.
§Treatment-only dominates no action because treatment-only saves lives and is less costly overall.
¶No. of weeks of prophylaxis for the respective risk and age groups.
1"Dominate" is a term used in cost-effectiveness analyses and refers to a strategy that is both more efficacious and less costly than another strategy.